Baldwin Wealth Partners
LGND icon

Baldwin Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Baldwin Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$279K Sell
893
-18
-2% -$5.32K 0.02% 192
2026
Q2 		$288K Buy
+911
New +$215K 0.02% 191
2024
Q4 		– Sell
-3,595
Closed -$360K – 673
2024
Q3 		$360K Buy
+3,595
New +$362K 0.02% 246

Other funds holding LGND

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Woodstock Corp
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
Isthmus Partners
Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return
Moody National Bank Trust Division
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

Baldwin Wealth Partners's LGND Position: Q3 2026 in Review

Baldwin Wealth Partners reduced its Ligand Pharmaceuticals (LGND) stake by 2% in Q3 2026, selling an estimated $5.32K and leaving 893 shares worth $279K. The position accounts for 0.02% of the portfolio, ranked #192.

Baldwin Wealth Partners first reported a position in LGND in Q3 2024 and has held it in 3 quarters since. The position peaked at $360K in Q3 2024. 98 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Baldwin Wealth Partners held 893 shares of Ligand Pharmaceuticals worth $279K as of Q3 2026.
  • Baldwin Wealth Partners sold 18 Ligand Pharmaceuticals shares in Q3 2026, an estimated $5.32K.
  • Ligand Pharmaceuticals made up 0.02% of Baldwin Wealth Partners's portfolio in Q3 2026, its #192 holding.
  • Baldwin Wealth Partners first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Baldwin Wealth Partners's Ligand Pharmaceuticals position peaked at $360K in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Baldwin Wealth Partners's 13F filing for Q3 2026, filed 13 Oct 2026.